LEXX vs. ALEC, SLN, COYA, BHST, IMUX, ELUT, ZURA, GNLX, OPTN, and ORMP
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Alector (ALEC), Silence Therapeutics (SLN), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), Immunic (IMUX), Elutia (ELUT), Zura Bio (ZURA), Genelux (GNLX), OptiNose (OPTN), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.
Lexaria Bioscience vs.
Alector (NASDAQ:ALEC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Alector presently has a consensus target price of $3.50, suggesting a potential upside of 207.02%. Lexaria Bioscience has a consensus target price of $7.00, suggesting a potential upside of 418.52%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Alector.
Lexaria Bioscience has lower revenue, but higher earnings than Alector. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
85.8% of Alector shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 9.1% of Alector shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Alector and Alector both had 3 articles in the media. Alector's average media sentiment score of 1.08 beat Lexaria Bioscience's score of 0.38 indicating that Alector is being referred to more favorably in the media.
Alector has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Alector has a net margin of -257.54% compared to Lexaria Bioscience's net margin of -1,473.04%. Lexaria Bioscience's return on equity of -88.88% beat Alector's return on equity.
Alector received 149 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 60.94% of users gave Alector an outperform vote.
Summary
Lexaria Bioscience beats Alector on 9 of the 17 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:LEXX) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy LEXX Stock Free LEXX Stock Alerts